Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI, a drug discovery company co-founded by serial ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI, the biotech drug developer spun out of Tempus ...
Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D ...
Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...
In another signal of the appetite among investors for companies applying artificial intelligence to drug discovery, Pathos AI has gathered an impressive $365 million in fourth-round financing as it ...
CHICAGO--(BUSINESS WIRE)--Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to ...
After a year of layoffs and declining share prices in the wake of a late-stage clinical failure, Rain Oncology’s search for a suitable buyer has paid off. AI-focused Pathos AI will pay $1.16 per share ...
When Maja Pencic set out to hit the Prague streets with her camera, she was determined to document the reality she found by asking direct questions.
Forbes contributors publish independent expert analyses and insights. Ollie Barder covers Japanese pop-culture and gaming from Tokyo. Set in the new Future Century, G Gundam takes place in the year ...
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights The tender offer expired as scheduled at one minute after 11:59 p.m., Eastern Time, on January 25, 2024. As of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results